Faruqi & Faruqi LLP Alerts Inovio Pharmaceuticals (INO) Shareholders About April 7, 2026 Legal Deadline

Faruqi & Faruqi, LLP, a nationally recognized securities litigation firm, has issued an important reminder to investors of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) regarding a pending securities class action lawsuit. The law firm urges shareholders who suffered financial losses in Inovio Pharmaceuticals to take immediate action before the April 7, 2026 deadline to seek appointment as lead plaintiff in the case.

This legal action centers around allegations that Inovio Pharmaceuticals and certain of its executives made false or misleading statements that potentially violated federal securities laws. Investors who purchased or otherwise acquired Inovio securities during the specified class period may be eligible to participate in the lawsuit and potentially recover damages.

Overview of the Securities Class Action

The securities class action lawsuit alleges that Inovio Pharmaceuticals, a biotechnology company focused on developing DNA-based immunotherapies and vaccines, made material misrepresentations or omissions that impacted shareholders. According to the complaint filed in federal court, these statements allegedly misled investors regarding the company's business operations, regulatory progress, and financial outlook.

As a result of these alleged misstatements, investors may have purchased INO stock at artificially inflated prices. When corrective disclosures were later made public, the company's stock price reportedly declined, causing significant losses to shareholders.

Key Allegations in the Complaint

The lawsuit claims that during the class period, Inovio Pharmaceuticals:

• Provided overly optimistic projections about product development timelines and regulatory approvals.
• Misrepresented the status and viability of certain vaccine and immunotherapy programs.
• Failed to disclose material risks and operational challenges that could negatively affect performance.
• Issued public statements that were allegedly inconsistent with internal data and regulatory realities.

These alleged actions are said to have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and related SEC rules.

Who May Be Affected?

Investors who purchased shares of Inovio Pharmaceuticals within the defined class period may be members of the proposed class. Shareholders who experienced financial losses due to the alleged misconduct are encouraged to consult with securities litigation counsel to understand their rights and options.

Importantly, investors do not need to serve as lead plaintiff to participate in any potential recovery. However, those wishing to serve in that leadership role must file a motion with the court before April 7, 2026.

What Is a Lead Plaintiff?

The lead plaintiff is typically the investor or small group of investors with the largest financial interest in the litigation. This individual represents the interests of all class members and works closely with counsel to guide the lawsuit. Courts often appoint the shareholder with the most substantial loss who meets certain adequacy and typicality requirements.

Faruqi & Faruqi encourages affected investors to contact the firm to discuss their eligibility and potential involvement.

Faruqi & Faruqi LLP: A Track Record of Investor Advocacy

Founded in 1995, Faruqi & Faruqi LLP has built a reputation as a trusted advocate for investors nationwide. The firm has offices in New York, Pennsylvania, California, and Georgia, and has successfully recovered hundreds of millions of dollars for shareholders in complex securities and corporate governance cases.

The firm emphasizes that it does not charge any upfront fees in securities class action cases. Legal fees and expenses are typically paid only if the case is successfully resolved in favor of investors.

How to Participate in the Lawsuit

Shareholders seeking more information about the Inovio Pharmaceuticals class action are encouraged to contact Faruqi & Faruqi directly through their official website or by telephone. Investors may also request a free case evaluation to determine eligibility.

It is important to act promptly, as the April 7, 2026 deadline is strictly enforced by the court. Failure to file a motion for lead plaintiff by this date may limit certain rights within the litigation.

Impact on Inovio Pharmaceuticals and Market Reaction

Inovio Pharmaceuticals, known for its DNA medicine technology platform, has faced scrutiny over its development programs in recent years. Market volatility and regulatory uncertainties have influenced investor confidence and stock performance.

While the company continues to advance its pipeline and pursue regulatory milestones, the pending securities litigation may present additional reputational and financial challenges. Market analysts note that class action lawsuits often create short-term stock pressure, although long-term outcomes depend on court proceedings and potential settlements.

Investor Rights and Securities Law Protections

Federal securities laws are designed to protect investors by requiring public companies to provide accurate and complete information. When companies allegedly fail to meet these standards, shareholders have the right to seek recourse through the courts.

Securities class actions serve as a mechanism to hold companies accountable and recover losses on behalf of affected investors. Participation in such lawsuits can help ensure transparency and reinforce market integrity.

Legal Deadline: April 7, 2026

The most critical takeaway for Inovio Pharmaceuticals investors is the April 7, 2026 deadline. Shareholders who wish to be considered for appointment as lead plaintiff must file their motion before this date. Missing the deadline may forfeit the opportunity to assume a leadership role in the case.

However, even investors who do not take action by the deadline may still remain part of the class and potentially benefit from any future recovery.

Final Thoughts for INO Investors

The securities class action against Inovio Pharmaceuticals underscores the importance of corporate transparency and investor vigilance. Shareholders who believe they have suffered losses should evaluate their legal options carefully and seek professional advice if necessary.

Faruqi & Faruqi LLP reiterates its commitment to protecting investor rights and encourages eligible INO investors to review the details of the case promptly.

As the April 7, 2026 deadline approaches, timely action could make a meaningful difference for affected shareholders seeking accountability and potential financial recovery.

#InovioPharmaceuticals #INOLawsuit #SecuritiesClassAction #InvestorAlert #SlimScan #GrowthStocks #CANSLIM